A group of scientists who believe the controversial herbal pain reliever kratom is being unfairly vilified in the wake of salmonella-related health warnings came together this week to blast the Food and Drug Administration's policies governing the substance and criticize Denver's prohibition of its sale for human consumption, with one expert suggesting that such approaches will inevitably lead to tragedy.
According to Jack Henningfield, an adjunct professor of behavioral biology at Johns Hopkins University School of Medicine, former opioid addicts who've successfully used kratom to kick their habit "are reporting they are terrified of losing access" to the product. "These people fear going back to opioids if kratom is banned, and any of us in addiction medicine know that fear is justified. It's predictable that many will go back to opioids and some will die."
Henningfield isn't an entirely neutral observer when it comes to kratom. He also serves as vice president of research in the areas of health policy and abuse liability for Pinney Associates, a firm that "helps our pharmaceutical and consumer healthcare clients to reduce their regulatory risk and enhance the commercial value of their life sciences products," according to its website — and he also provides scientific research guidance to the American Kratom Association.
Moreover, while neither Henningfield nor other speakers in the teleconference during which he made his remarks were paid for their participation, support for the event was provided by the nonprofit People Plants Health, and an industry voice was also on the agenda: Michael McGuffin, executive director of the American Herbal Products Association.
Then again, Henningfield's academic credentials are legitimate, as are those of the other two teleconferencers: Paula N. Brown, director of applied research and Canada research chair for the BC Institute of Technology and adjunct professor of biology at the University of British Columbia; and Oliver Grundmann, a clinical associate professor with the College of Pharmacy at the University of Florida.
All four experts delivered the same basic message: Rather than outlawing kratom or treating it similarly to narcotics such as heroin and cocaine, the FDA and other agencies in the federal government should regulate it to guarantee its quality, purity and consistency — and if they don't, a black market will develop that would likely put consumers at greater risk.
On the subject of Denver's human-consumption ban, Henningfield said such actions by local or state actors were predictable.
"When the FDA declared that kratom is an addictive, narcotic-like substance that's dangerous, it's not surprising" that Denver officials would come up with their own kratom rules, he allowed. "I am aware that many health professionals with different agencies are considering what to do, and they're scratching their head and getting mixed messages.... In the few states where it's banned, people get it from elsewhere, and if it's banned nationally and criminalized, the only place to go is criminal sources. And that's a deadly, scary option."
Added McGuffin: "The idea of having to understand 51 regulations — one from the FDA and then the fifty states — is not tenable. That's why we're strongly supportive of appropriate regulations and would discourage state-by-state approaches in the interest of maintaining order in the use of this herb that's being used in all fifty states. We advocate for strong federal management and regulation."
Grundmann discussed a survey he conducted two years ago with thousands of kratom users. "I can tell you that part of the responses I received came from Colorado," he noted. "I can't tell what part of that population was using kratom to mitigate withdrawal symptoms from either illicit drug use or prescription opioid use. But I would obviously share the caution or the concern that Dr. Henningfield feels that users who have been using kratom to mitigate withdrawal symptoms or [have] felt relief from symptoms of opioid use are now at a loss."
As a result of the Denver human-consumption ban, Grundmann went on, such individuals "might have to switch back to prescription opioids or turn back to illicit use — or they are obtaining kratom from other states or a source like the Internet, which obviously isn't regulated in the same manner. And that's a concern. I don't see any benefit in regulating it at this point on a state-by-state level, and I hope that eventually Denver and the states will try to find a way forward based on science — on what science tells us."
For her part, Brown said, "This really brings me back to my concern about the advisories issued by the FDA. The science out there doesn't support the assertion of the risks associated with kratom. This is a plant used for more than a century to reduce stress and anxiety, to boost energy and reduce minor pain — and there are few alternatives for reducing minor pain outside of Ibuprofen and Acetaminophen. From my perspective, you're talking about a traditionally used herb that is in the marketplace, and it's in the best interest of public health to make sure these products aren't adulterated and contaminated."
In February, of course, the FDA, in conjunction with the Centers for Disease Control and Prevention, targeted salmonella-infected kratom. Henningfield suggested that these efforts made sense. "That's when we need the FDA," he said. But in his view, using this situation as an excuse to justify prohibiting kratom in general would be as wrongheaded as banning all sales of chicken or eggs after a salmonella infection.
The speakers stressed that while kratom binds to the same receptors as heroin and fentanyl, it is infinitely less addictive than those substances. Nonetheless, there have been stories of users becoming addicted to kratom, as exemplified by our recent post "'Kratom Ruined My Life,' User Says." The source in that report revealed that he was an alcoholic who went back to consuming liquor in a desperate attempt to rid himself of a craving for kratom.
To that, Henningfield said, "We basically rank substances on their addictiveness and harmfulness. That's part of the scheduling process" established by the Drug Enforcement Administration. For instance, certain over-the-counter cough medicine "does cause addiction in some people and does cause serious harm. You could schedule it, but it makes more sense not to schedule it. Nicotine gum meets some criteria for addiction, and some people become addicted to it — but most of the people were already cigarette smokers."
In his view, "it's not as simple as all or none. ... Kratom's potential for addiction and harm is relatively low compared to opioids and other products and other substances. For example, narcotic-like opioids can cause powerful euphoria, as well as respiratory depression and death. We don't see that in kratom — not even in Southeast Asia, where it literally grows on trees. People don't smoke it there."
He points out that "the most widespread addiction on the planet is to caffeine" — an appropriate reference, since kratom is closely related to coffee. "We consider that a relatively benignly addictive substance. You could get stimulated and wake up with cocaine or amphetamines, but most of us believe caffeine is a better way to do it. If you drink it every day, you're probably at some level of dependence. But when it comes to opioids versus kratom, that's a no-brainer."
Grundmann, meanwhile, referenced the aforementioned survey, and from the results, "it is quite obvious that the risk of dependency development for kratom is low compared to many other drugs. As Dr. Henningfield pointed out, if we rank a drug or substance in general on a scale of how likely is somebody to get addicted or dependent on it, then kratom is likely to end up on the lower end of that. But there are various components that lead somebody to become dependent on a drug...and for somebody who was dependent on alcohol or wanted to use kratom to mitigate withdrawal symptoms from alcohol dependence, this might not be the ideal way to go about it."
Early evidence suggests that "kratom seems to be working quite well for withdrawal symptoms from opioids," Grundmann continued, "but we would really need larger studies that are better organized and better controlled to give us more evidence. And if research on kratom is restricted, those studies couldn't be conducted. That's the fear we have as researchers moving forward."
Keep Westword Free... Since we started Westword, it has been defined as the free, independent voice of Denver, and we would like to keep it that way. Offering our readers free access to incisive coverage of local news, food and culture. Producing stories on everything from political scandals to the hottest new bands, with gutsy reporting, stylish writing, and staffers who've won everything from the Society of Professional Journalists' Sigma Delta Chi feature-writing award to the Casey Medal for Meritorious Journalism. But with local journalism's existence under siege and advertising revenue setbacks having a larger impact, it is important now more than ever for us to rally support behind funding our local journalism. You can help by participating in our "I Support" membership program, allowing us to keep covering Denver with no paywalls.